The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause

Journal of Women's Health

Volumn 21, Issue 2, 2012, Pages 188-198

  Gallagher, J Christopher ^a   Strzinek, Robert A ^b   Cheng, Ru Fong J ^c   Ausmanas, Militza K ^c,d   Astl, Dorothea ^c   Seljan, Palma ^c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b Protenium Clinical Research   (United States)

^c PFIZER INC   (United States)

^d Western Institutional Review Board (IRB)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ABDOMINAL DISTENSION; ADULT; ARTICLE; ASTHENIA; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISCONTINUATION EMERGENT SIGN AND SYMPTOM; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DREAMING; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MENOPAUSE; MENTAL INSTABILITY; MOOD DISORDER; NAUSEA; NIGHTMARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SWEATING; VASODILATATION; VASOMOTOR DISORDER; XEROSTOMIA;

AGED; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NAUSEA; NEUROTRANSMITTER UPTAKE INHIBITORS; PATIENT SATISFACTION; POSTMENOPAUSE; VASOMOTOR SYSTEM;

EID: 84856647637     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2011.2764     Document Type: Article

References (20)

1. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
2. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978.
3. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-166. (Pubitemid 40189927)
4. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834. (Pubitemid 37430118)
5. Soares CN, Joffe H, Viguera AC, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med 2008;121:159-162.
6. Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006;13:568-575. (Pubitemid 44079527)
7. Barton DL, Lavasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28: 3278-3283.
8. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007;10:247-257.
9. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70: 332-337. (Pubitemid 28361490)
10. Wyeth Pharmaceuticals Inc. Pristiq package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc. 2010.
11. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for meno-pausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87.
12. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-172.e10.
13. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238e1-238e10.
14. Bouchard P, Panay N, de Villiers T, et al. Multicenter, randomized, double-blind, placebo-and active-controlled study of desvenlafaxine for treatment of vasomotor symptoms associated with menopause. Climacteric (in press).
15. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44:77-87. (Pubitemid 28305526)
16. Hill CD, Fehnel SE, Bobula JD, Yu H, McLeod LD. Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ). Menopause 2007;14:1047-1055. (Pubitemid 350098665)
17. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997;58(suppl 7):17-21.
18. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004;19:271-280. (Pubitemid 39141943)
19. Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005;89:207-212. (Pubitemid 41740850)
20. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psycho-pharmacol 2009;24:296-305.